The Efficacy of tadarafili for Bladder outlet obstruction and storage function: prospective urodynamic study

The Efficacy of tadarafili for Bladder outlet obstruction and storage function: prospective urodynamic study - UDS trial of tadarafili

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000017925

Enrollment

Registered

2015-06-25

Start date

2015-06-30

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

benign prostatic hyperplasia

Interventions

the oral administration of tadarafili

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: 1) I-PSS of 8 or higher 2) IPSS-QOL of 3 or higher 3) Prostate volume of 25 ml or higher 4) Qmax<15 ml/s with voided volume of 100 ml or more

Exclusion criteria

Exclusion criteria: Patients were excluded if they received oral treatment with alpha1-blockers, anticholinergic agents, antidepressants, 5ARI, anti-anxiety agents, or sex hormonal agents; had neurogenic bladder dysfunction, bladder calculi, or active urinary tract infection; had severe cardiac disease, renal dysfunction (serum-creatinine >2 mg/dL), hepatic dysfunction (aspartate aminotransferase and alanine aminotransferase more than twice the normal value).

Design outcomes

Primary

Measure	Time frame
The change of bladder outlet obstruction and storage function	—

Secondary

Measure	Time frame
The change of subjective parameters	—

Countries

Japan

Contacts

Public ContactYoshihisa Matsukawa

Nagoya University Graduate School of Medicine department of Urology

yoshi44@med.nagoya-u.ac.jp+81-52-744-2985

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026